Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases

Saputra, Pandit Bagus Tri; Kurniawan, Roy Bagus; Trilistyoati, Desy; Al-Farabi, Makhyan Jibril; Susilo, Hendri; Alsagaff, Mochamad Yusuf; Oktaviono, Yudi Her; Sutanto, Henry; Gusnanto, Arief; Wungu, Citrawati Dyah Kencono

doi:10.17305/bb.2022.8779

Cited by 3 publications

(2 citation statements)

References 208 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the literature reports 218 cases of COVID-19 vaccine-associated myocarditis [ 114 ]. In a recent systematic review, 396 published cases of myocarditis were reported, predominantly in male patients, following the administration of the second dose of the mRNA vaccine [ 115 ]. Notably, they experienced chest pain as a symptom.…”

Section: Complications Of Covid-19mentioning

confidence: 99%

The laboratory parameters in predicting the severity and death of COVID-19 patients: Future pandemic readiness strategies

Alsayed,

Ahmed,

AL Shweiki

et al. 2024

Biomol Biomed

View full text Add to dashboard Cite

The range of clinical manifestations associated with the infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encompasses a broad spectrum, ranging from flu-like symptoms to the occurrence of multiple organ failure and death. The severity of the coronavirus disease 2019 (COVID-19) is categorized based on clinical presentation and is divided into three distinct levels of severity identified as non-severe, severe, and critical. Although individuals of all age groups are susceptible to SARS-CoV-2 infection, middle-aged and older adults are more frequently impacted, with the latter being more likely to develop severe illness. Various laboratory characteristics observed in hospitalized COVID-19 patients have been correlated with adverse outcomes. These include elevated levels of D-dimer, liver enzymes, lactate dehydrogenase, C-reactive protein, ferritin, prothrombin time, and troponin, as well as decreased lymphocyte and platelets counts. This review investigated the relationship between baseline clinical characteristics, initial laboratory parameters upon hospital admission, and the severity of illness and mortality rates among COVID-19 patients. Although the COVID-19 pandemic has concluded, understanding the laboratory predictors of virus severity and mortality remains crucial, and examining these predictors can have long-term effects. Such insights can help healthcare systems manage resources more effectively and deliver timely and appropriate care by identifying and targeting high-risk individuals. This knowledge can also help us better prepare for future pandemics. By examining these predictors, we can take steps to protect public health and mitigate the impact of future pandemics.

show abstract

Section: Complications Of Covid-19mentioning

confidence: 99%

The laboratory parameters in predicting the severity and death of COVID-19 patients: Future pandemic readiness strategies

Alsayed,

Ahmed,

AL Shweiki

et al. 2024

Biomol Biomed

View full text Add to dashboard Cite

show abstract

“…Recent reviews on the issue have highlighted that in patients developing myocarditis after the SARS-CoV-2 mRNA vaccine, comorbidities are present in less than half the number of cases. In most cases, the underlying disease is represented by an inflammatory or autoimmune disorder, while a previous history of myocarditis is present in only about 10% of cases [25]. However, some cardiovascular conditions, such as arterial hypertension, hypercholesterolemia, and aortic root dilation, may also act as contributing factors in the development of SARS-CoV-2-related myocarditis [26].…”

Section: Comorbidities and Clinical Presentationmentioning

confidence: 99%

Diagnosis of Acute Myocarditis Following mRNA Vaccines against SARS-CoV-2: A Methodological Review

Zuin

Zimelli

Valle

et al. 2023

Viruses

View full text Add to dashboard Cite

The occurrence of acute myocarditis following the administration of mRNA vaccines against SARS-CoV-2 remains relatively rare, and it is associated with a very low mortality rate. The incidence varied by vaccine type, sex, and age and after the first, second, or third vaccination dose. However, the diagnosis of this condition often remains challenging. To further elucidate the relationship between myocarditis and SARS-CoV-2 mRNA vaccines, starting with two cases observed at the Cardiology Unit of the West Vicenza General Hospital located in the Veneto Region, which was among the first Italian areas hit by the COVID-19 pandemic, we performed a review of the available literature to highlight the clinical and diagnostic elements that could contribute to suspicion of myocarditis as an adverse event of SARS-CoV-2 immunization.

show abstract

Myocardial Infarction Following Vaccination Against COVID-19: A Systematic Review

Rahimi Petrudi,

Abdollahi,

Mirzaii-Dizgah

2023

Ann Mil Health Sci Res

View full text Add to dashboard Cite

Context: Several reports have been presented regarding the occurrence of acute myocardial infarction following vaccination against COVID-19. Objectives: The current systemic review tried to review and summarize the published evidence and documents regarding the occurrence of myocardial infarction following various types of anti-COVID-19 vaccines (AstraZeneca and Pfizer) and, finally, take steps to clarify the causes of such incidents. Methods: The relevant databases, including Medline, Web of Knowledge, Google Scholar, Scopus, and Cochrane, were comprehensively searched by the two blinded researchers for all eligible studies based on the considered keywords. Of 76 articles initially collected by database searching, 20 articles were included in the last analysis. Results: The occurrence of acute myocardial infarction was mostly related to SARS-CoV-2-based messenger RNA and viral vector vaccines. This cardiac attack occurred after the first vaccination in 74% of patients affected. The time of occurrence of myocardial infarction was also very different between different types of vaccines and varied between 15 minutes and 21 days after vaccination. Most of the myocardial infarctions that occurred after vaccination were of the ST-segment elevation type (STEMI) (23 of 28 patients). More than two-thirds of myocardial infarction cases occurred in patients who had significant cardiovascular risk profiles (hypertension, diabetes mellitus, and ischemic heart disease). Overall, 22.2% of cases suffering post-vaccination myocardial infarction died within hospitalization. Conclusions: The occurrence of myocardial infarction following the vaccination against COVID-19 is rare, and due to the fatality of this event, it is necessary to modify the biotechnological production of existing vaccines and to accurately evaluate the pathophysiology of this event.

show abstract

Myocarditis and coronavirus disease 2019 vaccination: A systematic review and meta-summary of cases

Cited by 3 publications

References 208 publications

The laboratory parameters in predicting the severity and death of COVID-19 patients: Future pandemic readiness strategies

The laboratory parameters in predicting the severity and death of COVID-19 patients: Future pandemic readiness strategies

Diagnosis of Acute Myocarditis Following mRNA Vaccines against SARS-CoV-2: A Methodological Review

Myocardial Infarction Following Vaccination Against COVID-19: A Systematic Review

Contact Info

Product

Resources

About